NCT03901469: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

NCT03901469
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have an inherited BRCA 1/2 mutation; Patients with inflammatory breast cancer
https://ClinicalTrials.gov/show/NCT03901469

Comments are closed.

Up ↑